Sphera Funds Management’s KalVista Pharmaceuticals KALV Stock Holding History

Sphera Funds Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-316,200	Closed	-$4.18M	–	83
2021 Q4	$4.18M	Buy	+316,200	New	+$5.03M	0.46%	59
2021 Q2	–	Sell	-258,880	Closed	-$6.65M	–	156
2021 Q1	$6.65M	Buy	258,880 +18,740	+8%	+$492K	0.51%	62
2020 Q4	$4.56M	Hold	240,140	–	–	0.4%	72
2020 Q3	$3.02M	Hold	240,140	–	–	0.3%	74
2020 Q2	$2.91M	Hold	240,140	–	–	0.27%	66
2020 Q1	$1.84M	Buy	240,140 +92,440	+63%	+$1.25M	0.23%	57
2019 Q4	$2.63M	Buy	+147,700	New	+$1.93M	0.22%	69
2016 Q1	–	Sell	-25,714	Closed	-$1.3M	–	106
2015 Q4	$1.3M	Sell	25,714 -2,857	-10%	-$150K	0.19%	102
2015 Q3	$1.43M	Hold	28,571	–	–	0.18%	109
2015 Q2	$2.86M	Buy	+28,571	New	+$2.83M	0.28%	95

Other funds holding KALV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sphera Funds Management's KALV Position: Q1 2022 in Review

Sphera Funds Management sold out of KalVista Pharmaceuticals (KALV) in Q1 2022, closing a stake of 316,200 shares — an estimated $4.18M sold.

Sphera Funds Management first reported a position in KALV in Q2 2015 and held it in 10 quarters. The position peaked at $6.65M in Q1 2021. 89 funds tracked by Wall St. Rank hold KALV as of Q1 2022.

Sphera Funds Management reported no remaining KalVista Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Sphera Funds Management sold 316,200 KalVista Pharmaceuticals shares in Q1 2022, an estimated $4.18M.
Sphera Funds Management first reported a position in KalVista Pharmaceuticals in Q2 2015 and held it in 10 quarters.
Sphera Funds Management's KalVista Pharmaceuticals position peaked at $6.65M in Q1 2021.
89 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2022.

Based on Sphera Funds Management's 13F filing for Q1 2022, filed 16 May 2022.